{"id":"W3135563856","doi":"10.1016/j.jtocrr.2021.100157","title":"Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"Boehringer Ingelheim; Pfizer Canada; AbbVie; Merck; AstraZeneca; Novartis; Pfizer; Takeda Pharmaceutical Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Internal medicine; Alectinib; ALK inhibitor; Anaplastic lymphoma kinase; Oncology; Ceritinib; Lung cancer; Context (archaeology); Population; Hazard ratio; Brain metastasis; Gastroenterology; Cancer; Metastasis; Confidence interval; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001330861,0.0001852823,0.0005945061,0.0001342914,0.0003504703,0.00006708204,0.0000393064,0.0001280745,0.0001935883],"category_scores_gemma":[0.002814516,0.0001169948,0.0001698763,0.0005125534,0.0002906496,0.0001177212,0.00008765765,0.0004765619,0.000002141898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003792646,"about_ca_system_score_gemma":0.0009225096,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001091847,"about_ca_topic_score_gemma":0.001582447,"domain_scores_codex":[0.996966,0.0001558565,0.0007171471,0.0007580759,0.0009373874,0.0004655144],"domain_scores_gemma":[0.9962939,0.0005344817,0.0001970984,0.0004348132,0.002105873,0.0004338317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004127546,0.0008023393,0.9658287,0.0001326237,0.0004701501,0.0003294283,0.0001598603,5.414316e-7,0.00006735256,0.0000436326,0.02130686,0.01044574],"study_design_scores_gemma":[0.003455289,0.0007013055,0.9591949,0.0005450843,0.0002520925,0.000008975235,0.00008625425,0.00001226457,0.0002613937,0.0001502011,0.03517802,0.0001542177],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824885,0.0007977174,0.00001072889,0.008169615,0.000806403,0.001770825,0.00007809635,0.00005745519,0.005820679],"genre_scores_gemma":[0.9752013,0.001139572,0.001283311,0.0002322978,0.000545539,0.000448444,0.0001905496,0.00004790088,0.02091107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01509039,"threshold_uncertainty_score":0.4770911,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05235902605818746,"score_gpt":0.4677355556769182,"score_spread":0.4153765296187307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}